Logo Lanfrica
  • Home
  • Atlas
  • Insights
  • Docs
  • Sign in

© 2026 Lanfrica. All rights reserved. All copyrights of the resources shown on the Lanfrica website belong to the original copyright holders, unless explicitly stated otherwise.

A phase 3, double-blind, randomized, active controlled study to evaluate the safety of MenAfriVac in healthy malians

Domain:

healthcare

Record type:

datasetpaper
Creator:
TapSowHaiDiallo, Fatoumata
Editor:
ETHETH
Publisher:
Oxford university Press
Host:avatar
Background. A safe, affordable, and highly immunogenic meningococcal A conjugate vaccine (PsA-TT, MenAfriVac) was developed to control epidemic group A meningitis in Africa. Documentation of the safety specifications of the PsA-TT vaccine was warranted, with sufficient exposure to detect potential rare vaccine-related adverse reactions. Methods. This phase 3, double-blind, randomized, active controlled clinical study was designed to evaluate the safety - primarily vaccine-related serious adverse events (SAEs) - up to 3 months after administration of a single dose of the PsA-TT vaccine to subjects aged 1-29 years in Mali. Safety outcomes were also compared to those following a single dose of a licensed meningococcal ACWY polysaccharide vaccine (PsACWY). Results. No vaccine-related SAEs occurred during the 3 months of follow-up of 4004 subjects vaccinated with a single dose of PsA-TT. When compared to PsACWY (1996 subjects), tenderness at the injection site appeared to be more frequent in the PsA-TT group. However, rates of local induration, systemic reactions, adverse events (AEs), and SAEs were similar in both groups, and unsolicited AEs and SAEs were all unrelated to the study vaccines. Conclusions. The study confirmed on a large scale the excellent safety profile of a single dose of PsA-TT when administered to its entire target population of 1-29 years of age.

Visit

doi.orghdl.handle.net

Tags

Active controlAfricaMenAfriVacRandomized clinical trialVaccine safety

Licenses

Creative Commons Attribution 4.0 Internationalhttps://creativecommons.org/licenses/by/4.0/legalcodeCreative Commons Attribution 4.0 Internationalhttps://creativecommons.org/licenses/by/4.0/legalcode

Similar

A Phase 2 Randomized, Double-Blind, Controlled Trial of the Safety and Immunogenicity of Typhoid Conjugate Vaccine (Vi-TCV) Among Children Younger Than 2 Years in Ouagadougou, Burkina FasoAdditional file 3 of A randomized, double-blind, phase 2b study to investigate the efficacy, safety, tolerability and pharmacokinetics of a single-dose regimen of ferroquine with artefenomel in adults and children with uncomplicated Plasmodium falciparum malariaSafety and efficacy of malaria vaccine candidate R21/Matrix-M in African children: a multicentre, double-blind, randomised, phase 3 trialEfficacy of four insect repellents against mosquito bites: a double‐blind randomized placebo‐controlled field study in SenegalAdvancing Global Health through Development and Clinical Trials Partnerships: A Randomized, Placebo-Controlled, Double-Blind Assessment of Safety, Tolerability, and Immunogenicity of PfSPZ Vaccine for Malaria in Healthy Equatoguinean MenThe Effect of Antibiotics on Post-adenotonsillectomy Morbidity in Tanzanian Children: Study Protocol for a Randomized Double-blind Placebo-controlled Trial

A Phase 2 Randomized, Double-Blind, Controlled Trial of the Safety and Immunogenicity of Typhoid Conjugate Vaccine (Vi-TCV) Among Children Younger Than 2 Years in Ouagadougou, Burkina Faso

Typhoid fever is an illness that may cause mild effects in children, such as fever and feeling tire

Additional file 3 of A randomized, double-blind, phase 2b study to investigate the efficacy, safety, tolerability and pharmacokinetics of a single-dose regimen of ferroquine with artefenomel in adults and children with uncomplicated Plasmodium falciparum malaria

Additional file 3. Pharmacokinetic analysis details. Supplementary document including tables and fig

Safety and efficacy of malaria vaccine candidate R21/Matrix-M in African children: a multicentre, double-blind, randomised, phase 3 trial

Efficacy of four insect repellents against mosquito bites: a double‐blind randomized placebo‐controlled field study in Senegal

Abstract Insect‐borne diseases represent a worldwide threat. In addition to fight against vectors (

Advancing Global Health through Development and Clinical Trials Partnerships: A Randomized, Placebo-Controlled, Double-Blind Assessment of Safety, Tolerability, and Immunogenicity of PfSPZ Vaccine for Malaria in Healthy Equatoguinean Men

Equatorial Guinea (EG) has implemented a successful malaria control program on Bioko Island. A highl

The Effect of Antibiotics on Post-adenotonsillectomy Morbidity in Tanzanian Children: Study Protocol for a Randomized Double-blind Placebo-controlled Trial

Abstract Background Adenotonsillectomy is the most frequently performed operation in child